- Home
- BIIB vs WSO Comparison
BIIB vs WSO Comparison
Compare BIIB & WSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- WSO
- Stock Information
- Founded
- BIIB 1978
- WSO 1945
- Country
- BIIB United States
- WSO United States
- Employees
- BIIB 7605
- WSO 7295
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- WSO Industrial Machinery/Components
- Sector
- BIIB Health Care
- WSO Consumer Discretionary
- Exchange
- BIIB Nasdaq
- WSO Nasdaq
- Market Cap
- BIIB 18.8B
- WSO 18.6B
- IPO Year
- BIIB 1991
- WSO N/A
- Fundamental
- Price
- BIIB $131.20
- WSO $442.91
- Analyst Decision
- BIIB Buy
- WSO Hold
- Analyst Count
- BIIB 26
- WSO 5
- Target Price
- BIIB $194.95
- WSO $478.75
- AVG Volume (30 Days)
- BIIB 1.7M
- WSO 294.2K
- Earning Date
- BIIB 05-01-2025
- WSO 04-23-2025
- Dividend Yield
- BIIB N/A
- WSO 2.71%
- EPS Growth
- BIIB 26.39
- WSO 0.29
- EPS
- BIIB 10.12
- WSO 13.03
- Revenue
- BIIB $9,816,400,000.00
- WSO $7,584,412,000.00
- Revenue This Year
- BIIB N/A
- WSO $5.13
- Revenue Next Year
- BIIB N/A
- WSO $5.29
- P/E Ratio
- BIIB $12.83
- WSO $34.03
- Revenue Growth
- BIIB 1.59
- WSO 3.92
- 52 Week Low
- BIIB $110.04
- WSO $435.58
- 52 Week High
- BIIB $238.00
- WSO $571.42
- Technical
- Relative Strength Index (RSI)
- BIIB 59.82
- WSO 36.21
- Support Level
- BIIB $123.97
- WSO $435.58
- Resistance Level
- BIIB $132.94
- WSO $462.91
- Average True Range (ATR)
- BIIB 3.49
- WSO 11.37
- MACD
- BIIB 1.04
- WSO -2.87
- Stochastic Oscillator
- BIIB 88.37
- WSO 12.08
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About WSO Watsco Inc.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.